Sunshine Biopharma Reports Series B Warrant Exercise Price Reduction

What Happened
Sunshine Biopharma Inc. (SBFM) filed an 8-K (Item 8.01) on September 11, 2026, announcing that the exercise price of its outstanding Series B Warrants has been reduced to $1.2046. The company says the reduction resulted from recent sales of its common stock under its previously disclosed at-the-market (ATM) offering. The new exercise price is subject to further adjustment as set forth in the terms of the Series B Warrants.

Key Details

• Filing: Form 8-K, Item 8.01, filed September 11, 2026.
• New exercise price: $1.2046 per share for outstanding Series B Warrants.
• Reason: Adjustment triggered by recent sales of common stock under the company’s previously disclosed at-the-market offering.
• Future changes: Exercise price may be further adjusted according to the warrant agreement terms.

Why It Matters
A lower exercise price means warrant holders can buy shares at a cheaper price, which can increase the likelihood of exercise and lead to more shares being issued if they are exercised. That can dilute existing shareholders and change the company’s share count and the cash proceeds the company would receive per exercised warrant. Investors should watch for any further adjustments under the warrant terms and for additional disclosures about ATM sales, warrant exercises, or changes to share count.